Your browser doesn't support javascript.
loading
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
van der Noll, Ruud; Jager, Agnes; Ang, Joo Ern; Marchetti, Serena; Mergui-Roelvink, Marja W J; de Bono, Johann S; Lolkema, Martijn P; de Jonge, Maja J A; van der Biessen, Diane A; Brunetto, Andre T; Arkenau, Hendrik-Tobias; Tchakov, Ilian; Beijnen, Jos H; De Grève, Jacques; Schellens, Jan H M.
Afiliação
  • van der Noll R; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. r.vd.noll@nki.nl.
  • Jager A; Department of Medical Oncology, Erasmus University MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands.
  • Ang JE; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.
  • Marchetti S; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • Mergui-Roelvink MWJ; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
  • de Bono JS; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.
  • Lolkema MP; Department of Medical Oncology, Erasmus University MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands.
  • de Jonge MJA; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.
  • van der Biessen DA; Department of Medical Oncology, Erasmus University MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands.
  • Brunetto AT; Department of Medical Oncology, Erasmus University MC Cancer Institute, PO Box 5201, 3008 AE, Rotterdam, The Netherlands.
  • Arkenau HT; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.
  • Tchakov I; The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.
  • Beijnen JH; AstraZeneca, Alderley Park, Park Estate, Macclesfield, SK10 4TF, UK.
  • De Grève J; Eisai, Mosquito Way, Hatfield, AL10 9SN, UK.
  • Schellens JHM; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
Invest New Drugs ; 38(4): 1096-1107, 2020 08.
Article em En | MEDLINE | ID: mdl-31637669
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatina / Paclitaxel / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Protocolos de Quimioterapia Combinada Antineoplásica / Carboplatina / Paclitaxel / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article